
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Breeze Holdings Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
YD Bio Announces Closing of Business Combination and Listing on the Nasdaq Global Market
Details : The Company is advancing corneal stem cell and exosome technologies for the treatment of ocular diseases such as dry eye syndrome, glaucoma, and corneal injury.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 30, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Breeze Holdings Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
